A wide range of electronic databases were searched from 1980 to May 2004. Reference lists of included studies were screened, experts and manufacturers were contacted and urological journals were handsearched.
Eligible studies compared the cancer yield of a systematic prostate biopsy scheme (index test) with any systematic reference scheme in the same population of men. Studies that did not compare the tests in the same population, non-systematic biopsies and computer simulation studies were excluded. The primary measure of comparison between index test (in general the standard sextant scheme) and reference test was the relative positivity rate (RPR) of the index test. Where appropriate, data were pooled using a random-effects model.